

Remarks

Currently Claims 1-24 and 41 are pending. Claims 25-40 are canceled.


The specification has been amended to recite the claim of priority and to include an abstract on a separate page.

Claims 3-13, 15-16 and 18-24 are amended herein to remove multiple dependencies for the purpose of reducing claim fees. The foregoing amendments do not narrow the scope of the claims and are not made for purposes of patentability.

New claim 41 is added. Support for this claim may be found throughout Applicants' specification including at pages 16-22 and the examples. No new matter is added.

Applicant respectfully submits that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at 919 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 17 May 2005
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
email: Lorie.A.Morgan@gsk.com